Compare Ferrari NV (RACE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Regeneron Pharmaceuticals Inc — how do they compare? Ferrari NV trades at $371.61 (market cap $65.25B), while Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B). The key difference: Ferrari NV and Regeneron Pharmaceuticals Inc are close in size by market cap, and Ferrari NV pays the higher dividend (1.14%). Which is the better fit depends on your goals.
| RACE | REGN | |
|---|---|---|
Market Cap | $65.25B | $70.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $517.65 | $812.27 |
52-Week Low | $314.63 | $545.46 |
Enterprise Value | $66.46B | $64.74B |
Dividend Yield | 1.14% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $369.97, down 1.82% today, with a bullish technical outlook supported by moving averages and key support at $370. The company demonstrates strong fundamentals with consistent earnings beats, a 22.19% net margin, and robust cash flow from operations of $2.35B in 2025. Recent news highlights ongoing share buybacks and the upcoming Q2 2026 earnings report on July 30.
The investment outlook remains positive given Ferrari's premium brand positioning, pricing power, and analyst consensus price target of $467.50 implying 26% upside. Risks include execution challenges with new EV models, economic sensitivity, and high valuation multiples. Wall Street sentiment is strongly bullish with 72% buy ratings.
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
